Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia

BACKGROUND: Oestrogen receptor positive, human epidermal growth factor receptor-2 (HER2) negative breast cancer (BC) is the most frequently diagnosed BC subtype. Combinations of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with anti-oestrogen therapy have led to improved survival compared with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Low, Jia Li, Lim, Elaine, Bharwani, Lavina, Wong, Andrea, Wong, Karmen, Ow, Samuel, Lim, Siew Eng, Lee, Matilda, Choo, Joan, Lim, Joline, Chan, Gloria, Walsh, Robert John, Muthu, Vaishnavi, Ngoi, Natalie, Chong, Wanqin, Tan, Sing Huang, Lee, Soo Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772978/
https://www.ncbi.nlm.nih.gov/pubmed/36570409
http://dx.doi.org/10.1177/17588359221139678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772978/
https://www.ncbi.nlm.nih.gov/pubmed/36570409
http://dx.doi.org/10.1177/17588359221139678

Ejemplares similares